These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 11979435)

  • 1. Constructing an adenocarcinoma vaccine: immunization of mice with synthetic KH-1 nonasaccharide stimulates anti-KH-1 and anti-Le(y) antibodies.
    Ragupathi G; Deshpande PP; Coltart DM; Kim HM; Williams LJ; Danishefsky SJ; Livingston PO
    Int J Cancer; 2002 May; 99(2):207-12. PubMed ID: 11979435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of selected LeY and KH-1 analogues: a medicinal chemistry approach to vaccine optimization.
    Spassova MK; Bornmann WG; Ragupathi G; Sukenick G; Livingston PO; Danishefsky SJ
    J Org Chem; 2005 Apr; 70(9):3383-95. PubMed ID: 15844973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of sialyl Lewis(a) (sLe (a), CA19-9) and construction of an immunogenic sLe(a) vaccine.
    Ragupathi G; Damani P; Srivastava G; Srivastava O; Sucheck SJ; Ichikawa Y; Livingston PO
    Cancer Immunol Immunother; 2009 Sep; 58(9):1397-405. PubMed ID: 19190907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells.
    Ragupathi G; Howard L; Cappello S; Koganty RR; Qiu D; Longenecker BM; Reddish MA; Lloyd KO; Livingston PO
    Cancer Immunol Immunother; 1999 Apr; 48(1):1-8. PubMed ID: 10235483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines.
    Ragupathi G; Cappello S; Yi SS; Canter D; Spassova M; Bornmann WG; Danishefsky SJ; Livingston PO
    Vaccine; 2002 Jan; 20(7-8):1030-8. PubMed ID: 11803062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.
    Ragupathi G; Livingston PO; Hood C; Gathuru J; Krown SE; Chapman PB; Wolchok JD; Williams LJ; Oldfield RC; Hwu WJ
    Clin Cancer Res; 2003 Nov; 9(14):5214-20. PubMed ID: 14614001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel and efficient method for synthetic carbohydrate conjugate vaccine preparation: synthesis of sialyl Tn-KLH conjugate using a 4-(4-N-maleimidomethyl) cyclohexane-1-carboxyl hydrazide (MMCCH) linker arm.
    Ragupathi G; Koganty RR; Qiu D; Lloyd KO; Livingston PO
    Glycoconj J; 1998 Mar; 15(3):217-21. PubMed ID: 9579798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial.
    Sabbatini PJ; Kudryashov V; Ragupathi G; Danishefsky SJ; Livingston PO; Bornmann W; Spassova M; Zatorski A; Spriggs D; Aghajanian C; Soignet S; Peyton M; O'Flaherty C; Curtin J; Lloyd KO
    Int J Cancer; 2000 Jul; 87(1):79-85. PubMed ID: 10861456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative immunological studies of tumor-associated Lewis X, Lewis Y, and KH-1 antigens.
    Guo J; Jiang W; Li Q; Jaiswal M; Guo Z
    Carbohydr Res; 2020 Jun; 492():107999. PubMed ID: 32272238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.
    Slovin SF; Ragupathi G; Musselli C; Fernandez C; Diani M; Verbel D; Danishefsky S; Livingston P; Scher HI
    Cancer Immunol Immunother; 2005 Jul; 54(7):694-702. PubMed ID: 15726361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the power of chemical synthesis: immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines.
    Ragupathi G; Coltart DM; Williams LJ; Koide F; Kagan E; Allen J; Harris C; Glunz PW; Livingston PO; Danishefsky SJ
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13699-704. PubMed ID: 12359877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers.
    Ragupathi G; Koide F; Sathyan N; Kagan E; Spassova M; Bornmann W; Gregor P; Reis CA; Clausen H; Danishefsky SJ; Livingston PO
    Cancer Immunol Immunother; 2003 Oct; 52(10):608-16. PubMed ID: 12811527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine.
    Slovin SF; Ragupathi G; Musselli C; Olkiewicz K; Verbel D; Kuduk SD; Schwarz JB; Sames D; Danishefsky S; Livingston PO; Scher HI
    J Clin Oncol; 2003 Dec; 21(23):4292-8. PubMed ID: 14645418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine.
    MacLean GD; Reddish MA; Koganty RR; Longenecker BM
    J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):59-68. PubMed ID: 8859725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21.
    Helling F; Zhang S; Shang A; Adluri S; Calves M; Koganty R; Longenecker BM; Yao TJ; Oettgen HF; Livingston PO
    Cancer Res; 1995 Jul; 55(13):2783-8. PubMed ID: 7796403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21.
    Ragupathi G; Meyers M; Adluri S; Howard L; Musselli C; Livingston PO
    Int J Cancer; 2000 Mar; 85(5):659-66. PubMed ID: 10699946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The immunogenicity of the tumor-associated antigen Lewis(y) may be suppressed by a bifunctional cross-linker required for coupling to a carrier protein.
    Buskas T; Li Y; Boons GJ
    Chemistry; 2004 Jul; 10(14):3517-24. PubMed ID: 15252797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward optimized carbohydrate-based anticancer vaccines: epitope clustering, carrier structure, and adjuvant all influence antibody responses to Lewis(y) conjugates in mice.
    Kudryashov V; Glunz PW; Williams LJ; Hintermann S; Danishefsky SJ; Lloyd KO
    Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3264-9. PubMed ID: 11248067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21.
    Gilewski TA; Ragupathi G; Dickler M; Powell S; Bhuta S; Panageas K; Koganty RR; Chin-Eng J; Hudis C; Norton L; Houghton AN; Livingston PO
    Clin Cancer Res; 2007 May; 13(10):2977-85. PubMed ID: 17504999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cancer vaccine based on fluorine-modified sialyl-Tn induces robust immune responses in a murine model.
    Song C; Zheng XJ; Liu CC; Zhou Y; Ye XS
    Oncotarget; 2017 Jul; 8(29):47330-47343. PubMed ID: 28537884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.